
 SENDERRA <small>Specialty Pharmacy</small> 3712 E. Plano Parkway, Ste. 200 Plano, TX 75074 <small>This prescription form is to be sent & received via fax</small>	Dermatology Injectable Enrollment Form A-D Physician Offices Call: 855-460-7928 Fax: 888-777-5645	Prescriber: Supervising Physician: Address: Phone: Contact:	NPI: NPI: Tax ID: Fax:
--	--	--	---

PATIENT INFORMATION			
Name:	<input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Trans M <input type="checkbox"/> Trans F <input type="checkbox"/> Other	DOB: ____/____/____	SS#: ____-____-____
Street:	City:	State: ____	ZIP: ____-____
Phone:	Alt. Phone:	<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other: _____	Wt.: ____ Ht.: ____

PRESCRIPTION			
Has the patient received a loading dose/starter kit? <input type="checkbox"/> Yes Start Date: ____/____/____ <input type="checkbox"/> No			
SHIP TO: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Doctor's Office <input type="checkbox"/> Other: _____			

Drug	Directions & Quantity	Refills
Bimzelx® <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> Autoinjector	<input type="checkbox"/> INITIAL: Inject 320 mg SQ on week 0, 4, 8, 12, and 16 (Quantity: 5) <input type="checkbox"/> MAINTENANCE: Inject 320 mg SQ every 8 weeks (Quantity: 1) <input type="checkbox"/> MAINTENANCE: Inject 320 mg SQ every 4 weeks (Quantity: 1) <div style="text-align: right; font-size: small;">***Intended for patients ≥ 120 kg (264 lbs)***</div>	
Cimzia® <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> Vials	<input type="checkbox"/> Inject 400 mg SQ every other week (Quantity: 4) <input type="checkbox"/> INITIAL: Inject 400 mg (two 200 mg injections) SQ on week 0, 2, 4 (Quantity: 6) <input type="checkbox"/> MAINTENANCE: Inject 200 mg SQ every other week starting on week 6 (Quantity: 2) <div style="text-align: right; font-size: small;">***Intended for patients ≤ 90 kg (198 lbs)***</div>	
Cosentyx® <input type="checkbox"/> Sensoready® Pen <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> Sensoready® Pen <input type="checkbox"/> UnoReady® Pen <input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 150 mg SQ on week 0, 1, 2, 3, and 4 (Quantity: 5) <input type="checkbox"/> MAINTENANCE: Inject 150 mg SQ every 4 weeks (Quantity: 1) <input type="checkbox"/> INITIAL: Inject 300 mg SQ on week 0, 1, 2, 3, and 4 (Quantity: QS 5 doses) <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every 4 weeks (Quantity: QS 28 days)	
Dupixent® <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe	<input type="checkbox"/> INITIAL: Inject 600 mg SQ (two 300 mg injections) at week 0 (Quantity: 2) <input type="checkbox"/> MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 2)	

MEDICAL INFORMATION				
PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY				
PREVIOUS THERAPIES: <input type="checkbox"/> Methotrexate <input type="checkbox"/> Soriatane <input type="checkbox"/> Clobetasol <input type="checkbox"/> Humira <input type="checkbox"/> Enbrel <input type="checkbox"/> _____	Tried & Failed (Duration): <input type="checkbox"/> (_____) <input type="checkbox"/> (_____) <input type="checkbox"/> (_____) <input type="checkbox"/> (_____) <input type="checkbox"/> (_____) <input type="checkbox"/> (_____)	Not Tolerated: <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	Contraindication: _____ _____ _____ _____ _____ _____	 Affected Areas <input type="checkbox"/> Face <input type="checkbox"/> Feet <input type="checkbox"/> Groin <input type="checkbox"/> Hands <input type="checkbox"/> Nails <input type="checkbox"/> Scalp <input type="checkbox"/> Other: _____ BSA % PASI Score _____
PHOTOTHERAPY <input type="checkbox"/> UVA /UVB <input type="checkbox"/> Patient cannot afford	Tried & Failed (Duration): <input type="checkbox"/> (_____) <input type="checkbox"/> Photosensitivity	Not Tolerated: <input type="checkbox"/> <input type="checkbox"/> Risk of Skin Cancer	Contraindication: <input type="checkbox"/> Distance from Office	Allergies: _____
<input type="checkbox"/> L12.0 Bullous Pemphigoid <input type="checkbox"/> L40.0 Psoriasis Vulgaris (Plaque Psoriasis) <input type="checkbox"/> Other: _____	<input type="checkbox"/> L28.1 Prurigo Nodularis <input type="checkbox"/> L50.8 Other Urticaria			

Active TB is ruled out: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: ____/____/____	Hep B ruled out/treated: <input type="checkbox"/> Yes <input type="checkbox"/> No Date: ____/____/____
---	--

Additional Clinical Information:

American Academy of Dermatology Consensus Statement on Psoriasis Therapies		
<input type="checkbox"/> Psoriasis is covering greater than 10% of body surface area	<input type="checkbox"/> Psoriasis is on palms, soles, head and neck, or genitalia	<input type="checkbox"/> Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints
<input type="checkbox"/> Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships		

INJECTION TRAINING
<input type="checkbox"/> Patient has received pen and injection training <input type="checkbox"/> Physician's office to provide injection training <input type="checkbox"/> Senderra to coordinate injection training

PRESCRIBER SIGNATURE
To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

Prescriber: _____	Date: ____/____/____
--------------------------	-----------------------------

CONFIDENTIALITY NOTICE
IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.